MTMohammad Javad Taghipour

Mohammad Javad Taghipour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Javad Taghipour has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vitro and in silico studies for the identification of anti-cancer and antibacterial peptides from camel milk protein hydrolysates

    by Mohammad Javad Taghipour, Hamid Ezzatpanah, Mohammad Ghahderijani

    Today, breast cancer and infectious diseases are very worrying that led to a widespread effort by researchers to discover natural remedies with no side effects to fight them. In the present study, we isolated camel milk protein fractions, casein and whey proteins, and hydrolyzed them using pepsin, trypsin, and both enzymes. Screening of peptides with anti-breast cancer and antibacterial activity against pathogens was performed. Peptides derived from whey protein fraction with the use of both enzymes showed very good activity against MCF-7 breast cancer with cell viability of 7.13%. The separate use of trypsin and pepsin to digest whey protein fraction yielded peptides with high antibacterial activity against S. aureus (inhibition zone of 4.17 ± 0.30 and 4.23 ± 0.32 cm, respectively) and E. coli (inhibition zone of 4.03 ± 0.15 and 4.03 ± 0.05 cm, respectively). Notably, in order to identify the effective peptides in camel milk, its protein sequences were retrieved and enzymatically digested in silico. Peptides that showed both anticancer and antibacterial properties and the highest stability in intestinal conditions were selected for the next step. Molecular interaction analysis was performed on specific receptors associated with breast cancer and/or antibacterial activity using molecular docking. The results showed that P3 (WNHIKRYF) and P5 (WSVGH) peptides had low binding energy and inhibition constant so that they specifically occupied active sites of protein targets. Our results introduced two peptide-drug candidates and new natural food additive that can be delivered to further animal and clinical trials.


  • Therapeutic Approaches for COVID-19 Based on the Interferon-Mediated Immune Responses

    by Manica Negahdaripour, Pouria Mosaddeghi, Farbod Shahabinezhad, Zahra Dehghani, Mitra Farahmandnejad, Mohammad Javad Taghipour, Mohsen Moghadami, Navid Nezafat, Seyed Masoom Masoompour

    Background: As the outbreak of COVID-19 has accelerated, an urgent need for finding strategies to combat the virus is growing. Thus, gaining more knowledge on the pathogenicity mechanism of SARS-CoV-2, i.e. the causing agent of COVID-19, and its interaction with the immune system is of utmost importance. Although this novel virus is not well known yet, its structural and genetic similarity with SARS-CoV as well as the comparable pattern of age-mortality relations suggest that some previous findings on SARS could be applicable for COVID-19. Objective: The aim of this study was to investigate the most important signaling pathways activated by coronaviruses to better understand the viral pathogenesis and host immune responses. Method: Here, a systems biology study was conducted on a SARS database. It was followed by a literature review on the cognate subject. Results: It was proved that interferons may possess a crucial role in the defense against coronavirus diseases. The literature supported the validity of the employed approach and the notion that interferon induction could play a key role in the body defense against coronavirus infections. Conclusion: Altogether, administration of interferons or interferon-inducing agents in a prophylactic manner or at the early stages of the disease, could mimic the effective antiviral responses against SARS-CoV-2 and reduce the disease severity. At later stages of the disease, however, the balance of the immune reactions would be disrupted and the responses would shift toward immunopathogenic over-reactions, which could be exacerbated by the interferon usage. Moderating the activity of the immune system by anti-inflammatory agents, might be the optimum approach in such conditions.